In mice treated with HFLPD, this expression was reduced; this suggested that our supplemented probiotic might be efficient in protecting the liver from diet-induced obesity and metabolic changes in the liver by inhibiting the carcinogenic marker MYL9. The gene discussed is MYL9; the disease is obesity disorder.